PRMT5 as a druggable target for glioblastoma therapy

BACKGROUND: In spite of standard multimodal therapy consisting of surgical resection followed by radiation and concurrent chemotherapy, prognosis for glioblastoma (GBM) patients remains poor. The identification of both differentiated and undifferentiated “stem cell like” populations in the tumor hig...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Banasavadi-Siddegowda, Yeshavanth Kumar, Welker, Alessandra M, An, Min, Yang, Xiaozhi, Zhou, Wei, Shi, Guqin, Imitola, Jaime, Li, Chenglong, Hsu, Sigmund, Wang, Jiang, Phelps, Mitch, Zhang, Jianying, Beattie, Christine E, Baiocchi, Robert, Kaur, Balveen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Basic and Translational Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961180/
https://ncbi.nlm.nih.gov/pubmed/29106602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox206
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller